12.09
+12.99%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Quidel
From its filings with the US Securities and Exchange Commission
Quidel is based in San Diego, California. Its shares trade on Nasdaq under the ticker QDEL. The SEC classifies its business as in vitro & in vivo diagnostic substances. In the fiscal year to 28 December 2025, it reported revenue of $2.73bn and a net loss of $1.13bn. At that date it held total assets of $5.77bn and shareholders' equity of $1.92bn. By region, Domestic accounted for 52.6%, followed by Foreign at 47.4%.
Our vision is to advance diagnostics to power a healthier future. With our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, we aim to support clarity for clinicians and patients to help create better health outcomes. Our global infrastructure and commercial reach support our customers across more than 140 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. We operate globally with manufacturing facilities in the U.S., U.K. and China and with sales centers, administrative offices and warehouses located throughout the world.
We currently sell our products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other POC settings, blood banks and donor centers, as well as for individual, non-professional, OTC use.
We provide diagnostic testing solutions under various registered and unregistered brand names, including, among others, the following: ADENOPLUS™, BIOVUE™, FRESHCELLS™, INFLAMMADRY™, LYRA™, METERPRO™, MICROVUE™, ORTHO™, Ortho Clinical Diagnostics™, ORTHO OPTIX™, ORTHO VERSEIA™, ORTHO VISION™, QUICKVUE™, QUIDEL™, QuidelOrtho™, QuidelOrtho AUTOMATION ROUTING™, QuidelOrtho PERFORMANCE MANAGER™, QuidelOrtho RESULTS MANAGER™, SAVANNA™, SOFIA™, SOLANA™, THYRETAIN™, TRIAGE™, VALUMETRIX™, VIRENA™ and VITROS™.
Quoted from its 10-K, filed 19 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 5 Aug 1981
- Employees
- 6,500
- Website
- quidel.com ↗
- Head office
- 9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA, 92121
- Classification
- In Vitro & In Vivo Diagnostic Substances
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Kenneth BuechlerIndependent Chairman of the Board$309,781
- Mr. Douglas BryantPresident, Chief Executive Officer, Director, since 2009$7.2m
- Mr. Randall StewardChief Financial Officer$2.5m
- Mr. Robert BujarskiChief Operating Officer$2.2m
- Ms. Michelle HodgesSenior Vice President, General Counsel
- Mr. William FerenczySenior Vice President - Cardiometabolic Business Unit
- Ms. Karen GibsonSenior Vice President - Digital Health Business Unit
- Dr. Werner KrollSenior Vice President - R&D$2.5m
- Dr. Tamara RanalliSenior Vice President - Molecular Business
- Mr. Edward RussellSenior Vice President - Business Development$1.1m
- Mr. Edward MichaelIndependent Director$274,168
- Dr. Mary PolanIndependent Director$254,787
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 67
- Environment
- 54
- Social
- 75
- Governance
- 72
- Direct emissions (scope 1)
- 22,544 t
- Energy emissions (scope 2)
- 28,009 t
- Women in the workforce
- 40.55905%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established Reputation: Quidel Corp has built a strong reputation in the medical diagnostics industry.
- Innovative Product Range: The company offers a diverse portfolio of innovative diagnostic products.
- Strong Financial Position: Quidel Corp has a solid financial standing, allowing for strategic investments and expansion.
Weaknesses
- Dependence on External Suppliers: Quidel Corp relies on external suppliers for certain components, which may pose supply chain risks.
- Limited Global Presence: The company's market reach is relatively concentrated in certain regions, reducing international growth opportunities.
- Vulnerability to Regulatory Changes: Quidel Corp operates in a highly regulated industry, making it susceptible to changes in government policies.
Opportunities
- Increasing Demand for Rapid Diagnostic Tests: The global demand for fast and accurate diagnostic tests is on the rise, providing growth opportunities for Quidel Corp.
- Expansion into Emerging Markets: The company can explore untapped markets in developing countries, where there is a growing need for advanced medical diagnostics.
- Strategic Partnerships: Quidel Corp has the opportunity to establish strategic collaborations with healthcare providers or biotech firms to enhance its product offerings.
Threats
- Competition from Established Players: Quidel Corp faces intense competition from well-established companies in the medical diagnostics industry.
- Technological Advancements: Rapid advancements in technology may render some of Quidel Corp's existing products obsolete.
- Economic Uncertainty: Fluctuations in the global economy could impact customer spending and demand for medical diagnostics, affecting Quidel Corp's revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.